{"id":606355,"date":"2026-08-27T16:24:21","date_gmt":"2026-08-27T16:24:21","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/606355\/"},"modified":"2026-08-27T16:24:21","modified_gmt":"2026-08-27T16:24:21","slug":"prostate-cancer-nrg-gu005-defines-trade-offs-between-sbrt-and-moderately-hypofractionated-imrt","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/606355\/","title":{"rendered":"Prostate Cancer NRG-GU005 Defines Trade-Offs Between SBRT and Moderately Hypofractionated IMRT"},"content":{"rendered":"

In the international phase III NRG-GU005 trial, stereotactic body radiotherapy (SBRT) improved bowel-related quality of life vs moderately hypofractionated intensity-modulated radiotherapy (IMRT) in patients with favorable intermediate-risk prostate cancer. However, Ellis et al reported in JAMA<\/a> that SBRT did not improve urinary irritative\/obstructive\u2013related quality of life or demonstrate superior cancer control.<\/p>\n

\u201cThe treatment of prostate cancer with radiotherapy is evolving. How quickly radiotherapy can be delivered, and the relative risks and benefits of such a treatment, is of significant public interest,\u201d the investigators wrote. \u201cThis study has immediate impact on patients and physicians considering a shorter course of radiotherapy for localized prostate cancer.\u201d<\/p>\n

Study Details<\/p>\n

NRG-GU005 accrued patients with localized prostate cancer across 136 centers in Asia, Canada, Europe, and the United States. Eligible patients had clinical stage T1 to T2b disease with a Gleason score of 3 + 4 (Grade Group 2) and a prostate-specific antigen (PSA) level of less than 20 ng\/mL or a Gleason score of 3 + 3 (Grade Group 1) and a PSA level of 10 to 20 ng\/mL.<\/p>\n

A total of 698 patients (median age = 68 years) were randomly assigned in a 1:1 ratio to receive SBRT at 36.25 Gy in 5 fractions (n = 353) or moderately hypofractionated IMRT at 70 Gy in 28 fractions or 60 Gy in 20 fractions (n = 345).<\/p>\n

The primary outcomes of the trial were minimal clinically important declines in the Expanded Prostate Cancer Index Composite\u201326 Item (EPIC-26) urinary irritative\/obstructive and bowel domains at 2 years and disease-free survival at 3 years. Follow-up data were provided for a median of 3.2 years.<\/p>\n

Key Findings<\/p>\n

At 2 years, urinary irritative\/obstructive\u2013related quality-of-life outcomes were not found to differ between the SBRT and moderately hypofractionated IMRT groups (35.4% vs 33.7%; P = .68). Outcomes for urinary incontinence at 1 and 2 years and sexual function at 1 year appeared to favor SBRT. Grade 3 or 4 genitourinary adverse events were less frequent with SBRT than with moderately hypofractionated IMRT (0.6% vs 2.5%; P = .04). Fewer patients experienced a decline in bowel-related quality of life with SBRT vs moderately hypofractionated IMRT (34.9% vs 43.8%; P = .03).<\/p>\n

The 3-year disease-free survival rate was 92.1% (95% confidence interval [CI] = 88.9%\u201395.2%) with moderately hypofractionated IMRT vs 88.6% (95% CI = 85.2%\u201392.1%) with SBRT (one-sided log-rank P < .001 for futility). The biochemical disease\u2013free survival failure rate by PSA testing was higher with SBRT (7.8% vs 4.2%; P = .04).<\/p>\n

\u201cSBRT did not result in improved urinary irritative\/obstructive\u2013related quality of life compared with moderately hypofractionated IMRT at 2 years but did improve bowel-related quality of life,\u201d the investigators concluded. \u201cSBRT was not superior to moderately hypofractionated IMRT in terms of cancer control at 3 years.\u201d<\/p>\n

Looking ahead, the investigators noted that future research should explore differences in SBRT techniques for prostate cancer.<\/p>\n

Rodney J. Ellis, MD, of the University of South Florida, Tampa<\/a>, is the corresponding author of the article in JAMA.<\/p>\n

Disclosure: The study was supported by the National Cancer Institute and the Cancer Therapy Evaluation Program. For full disclosures of the study authors, visit jamanetwork.com<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"In the international phase III NRG-GU005 trial, stereotactic body radiotherapy (SBRT) improved bowel-related quality of life vs moderately…\n","protected":false},"author":2,"featured_media":606356,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-606355","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/606355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=606355"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/606355\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/606356"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=606355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=606355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=606355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}